Assessing the In Vitro and In Vivo Performance of L-Carnitine-Loaded Nanoparticles in Combating Obesity

Basit Öğe Kaydı
dc.authoridAnsari, Irfan Aamer/0000-0001-5375-0006
dc.authoridAnsari, Siddique Akber/0000-0003-3966-2282
dc.authoridMacit-Celebi, Melahat Sedanur/0000-0002-7480-1586
dc.authoridErgin, Ahmet Dogan/0000-0002-9387-0085
dc.authorwosidAnsari, Irfan Aamer/HTT-2735-2023
dc.authorwosidAnsari, Siddique Akber/M-4412-2017
dc.authorwosidErgin, Ahmet Dogan/AAO-1876-2021
dc.contributor.authorUner, Burcu
dc.contributor.authorErgin, Ahmet Dogan
dc.contributor.authorAnsari, Irfan Aamer
dc.contributor.authorMacit-Celebi, Melahat Sedanur
dc.contributor.authorAnsari, Siddique Akber
dc.contributor.authorKahtani, Hamad M. Al
dc.date.accessioned2024-06-12T11:09:14Z
dc.date.available2024-06-12T11:09:14Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAddressing obesity is a critical health concern of the century, necessitating urgent attention. L-carnitine (LC), an essential water-soluble compound, plays a pivotal role in lipid breakdown via beta-oxidation and facilitates the transport of long-chain fatty acids across mitochondrial membranes. However, LC's high hydrophilicity poses challenges to its diffusion through bilayers, resulting in limited bioavailability, a short half-life, and a lack of storage within the body, mandating frequent dosing. In our research, we developed LC-loaded nanoparticle lipid carriers (LC-NLCs) using economically viable and tissue-localized nanostructured lipid carriers (NLCs) to address these limitations. Employing the central composite design model, we optimized the formulation, employing the high-pressure homogenization (HPH) method and incorporating Poloxamer (R) 407 (surfactant), Compritol (R) 888 ATO (solid lipid), and oleic acid (liquid oil). A comprehensive assessment of nanoparticle physical attributes was performed, and an open-field test (OFT) was conducted on rats. We employed immunofluorescence assays targeting CRP and PPAR-gamma, along with an in vivo rat study utilizing an isolated fat cell line to assess adipogenesis. The optimal formulation, with an average size of 76.4 +/- 3.4 nm, was selected due to its significant efficacy in activating the PPAR-gamma pathway. Our findings from the OFT revealed noteworthy impacts of LC-NLC formulations (0.1 mg/mL and 0.2 mg/mL) on adipocyte cells, surpassing regular L-carnitine formulations' effects (0.1 mg/mL and 0.2 mg/mL) by 169.26% and 156.63%, respectively (p < 0.05).en_US
dc.description.sponsorshipThis research project was supported by the Researchers Supporting Project, number (RSPD2023R930), King Saud University, Riyadh, Saudi Arabia; Washington University Animal Diagnostic Lab (protocol no.: 04-2523); and Washington University Anesthesiology and [RSPD2023R930]; King Saud University, Riyadh, Saudi Arabia [04-2523]; Washington University Anesthesiology and Pharmacology Research Center Laben_US
dc.description.sponsorshipThis research project was supported by the Researchers Supporting Project, number (RSPD2023R930), King Saud University, Riyadh, Saudi Arabia; Washington University Animal Diagnostic Lab (protocol no.: 04-2523); and Washington University Anesthesiology and Pharmacology Research Center Lab. Their assistance was instrumental for the successful completion of this research.en_US
dc.identifier.doi10.3390/molecules28207115
dc.identifier.issn1420-3049
dc.identifier.issue20en_US
dc.identifier.pmid37894594en_US
dc.identifier.scopus2-s2.0-85175273807en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/molecules28207115
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22734
dc.identifier.volume28en_US
dc.identifier.wosWOS:001092561400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofMoleculesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNLCen_US
dc.subjectCarnitineen_US
dc.subjectObesityen_US
dc.subjectCell Cultureen_US
dc.subjectOpen-Field Testen_US
dc.subjectNanostructured Lipid Carriersen_US
dc.subjectActivated Receptor-Gammaen_US
dc.subjectDrug-Delivery Systemsen_US
dc.subjectPalmitoyl-L-Carnitineen_US
dc.subjectAcetyl-L-Carnitineen_US
dc.subjectTherapeutic-Useen_US
dc.subjectDesign Approachen_US
dc.subjectHplc Methoden_US
dc.subjectPpar-Gammaen_US
dc.subjectSupplementationen_US
dc.titleAssessing the In Vitro and In Vivo Performance of L-Carnitine-Loaded Nanoparticles in Combating Obesityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu